Comparison of Ibruttanib and FCR in FLAIR study and the potential benefits of a-calibrutinib in C-N-S prophylaxis

In recent years, there have been many advances in the treatment of lymphoma and chronic lymphocytic leukemia (CLL) in the UK. Several novel agents and clinical trials are emerging in both lymphoma and CLL, providing more options for patients.

In this exclusive podcast, leading experts Kate Cwynarski, FRCP, FCRPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, and Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, hold a fascinating discussion on recent updates in the lymphoma and CLL treatment landscape from a UK perspective. Dr Cwynarski and Dr Davies discuss several trials, including the POLARIX trial (NCT03274492), the FLAIR trial (ISRCTN01844152), the MARIETTA trial (NCT02329080), novel promising agents, and the future treatment of lymphoma.

The post Updates in lymphoma and CLL treatment in the UK appeared first on VJHemOnc.